SAN DIEGO, Jan. 16 /PRNewswire-FirstCall/ -- CryoCor, Inc. (Nasdaq:
CRYO), a medical device company focused on the treatment of cardiac
arrhythmias, announced today that it filed two patent infringement lawsuits
against CryoCath Technologies Inc., one in the United States District Court
for the District of Delaware and one in Canada.

The lawsuits allege that CryoCath's products infringe several patents
related to CryoCor's Cardiac Cryoablation System. CryoCor is an exclusive
licensee of the patents, and is seeking monetary damages and injunctions in
the United States and Canada to prohibit further infringement.

Ed Brennan, Ph.D., President and Chief Executive Officer of CryoCor,
said, "We believe that our exclusive license to these patents gives us
broad coverage over key technologies that are critical in the field of
cryoablation for cardiovascular applications. We have filed this lawsuit
against CryoCath to enforce our intellectual property rights related to
this critical segment of healthcare."

CryoCor has previously announced that it is pursuing patent
interference proceedings initiated in 2004 with the United States Patent
and Trademark Office. CryoCor's believes that it, through the licensor, was
the first to invent certain pre-cooling technologies and is seeking that an
interference be declared between CryoCath patents and CryoCor intellectual
property to determine right of invention and ownership. CryoCor reported
that it expects a patent interference proceeding to be declared by the
U.S.P.T.O. in the first half of 2008.

About CryoCor

CryoCor is a medical technology company that has developed and
manufactures a disposable catheter system based on its proprietary
cryoablation technology for the minimally invasive treatment of cardiac
arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation
System, or the Cryoablation System, is designed to treat cardiac
arrhythmias through the use of cryoenergy, or extreme cold, to destroy
targeted cardiac tissue. The Cryoablation System has been approved in
Europe for the treatment of atrial fibrillation, and atrial flutter, the
two most common and difficult to treat arrhythmias, since 2002. In the
United States, CryoCor is conducting a pivotal trial to evaluate the safety
and efficacy of the Cryoablation System for the treatment of atrial
fibrillation and the Cryoablation System has been approved for the
treatment of right atrial flutter. For more information please visit the
Company's website at http://www.cryocor.com

Forward Looking Statements

The statements in this press release that are not descriptions of
historical facts are forward-looking statements that are subject to risks
and uncertainties. These include statements related to the merits of
CryoCor's positions in its litigation and interference proceedings with
CryoCath and the possible outcome of that litigation and those interference
proceedings, all of which are prospective. Such statements are only
predictions and reflect CryoCor's expectations and assumptions as of the
date of this press release based on currently available operating,
financial, and competitive information. The actual events or results may
differ materially from those projected in such forward-looking statements
due to a number of factors, including risks involved with CryoCor's
technology; risks associated with the Company's dependence on patents and
proprietary rights; risks associated with the Company's protection and
enforcement of its patents and proprietary rights; risks associated with
the development or availability of competitive products or technologies and
the other risks and uncertainties identified in the Company's filings with
the Securities and Exchange Commission. These forward-looking statements
speak only as of the date hereof. The Company expressly disclaims any
intent or obligation to update any of these forward- looking statements.

(Date:12/7/2016)... Mich. , Dec. 7, 2016 Neogen ... has named Dr. Dan Kephart as its ... company. Kephart will assume his responsibilities at Neogen effective ... and development director for the agribusiness unit of Thermo ... safety development at Life Technologies. His extensive industry experience ...

(Date:12/7/2016)... SAN DIEGO , Dec. 7, 2016 Biocom, the ... community, issued the statement below following passage of 21 st ... the House on November 30 by a 392-26 vote and ... This statement may be attributed to Joe Panetta , ... historic legislation that will give hope to millions of patients ...

(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...

(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...

(Date:11/22/2016)... Nov. 22, 2016 MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Healthcare and Life Sciences Awards as "Most Outstanding ... an unprecedented year of recognition and growth for MedNet, ... 15 years. iMedNet ™ , ...